{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "6367635",
  "DateCompleted": {
    "Year": "1984",
    "Month": "04",
    "Day": "12"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "05",
    "Day": "26"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0066-4804",
      "JournalIssue": {
        "Volume": "25",
        "Issue": "1",
        "PubDate": {
          "Year": "1984",
          "Month": "Jan"
        }
      },
      "Title": "Antimicrobial agents and chemotherapy",
      "ISOAbbreviation": "Antimicrob Agents Chemother"
    },
    "ArticleTitle": "Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study.",
    "Pagination": {
      "StartPage": "20",
      "EndPage": "24",
      "MedlinePgn": "20-4"
    },
    "Abstract": {
      "AbstractText": [
        "As a possible treatment for common colds, we tested zinc gluconate lozenges in a double-blind, placebo-controlled, clinical trial. One 23-mg zinc lozenge or matched placebo was dissolved in the mouth every 2 wakeful h after an initial double dose. After 7 days, 86% of 37 zinc-treated subjects were asymptomatic, compared with only 46% of 28 placebo-treated subjects (P = 0.0005). Side effects or complaints were usually minor and consisted mainly of objectionable taste and mouth irritation. Zinc lozenges shortened the average duration of common colds by about 7 days."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Eby",
        "ForeName": "G A",
        "Initials": "GA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Davis",
        "ForeName": "D R",
        "Initials": "DR"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Halcomb",
        "ForeName": "W W",
        "Initials": "WW"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial",
      "Journal Article",
      "Randomized Controlled Trial"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Antimicrob Agents Chemother",
    "NlmUniqueID": "0315061",
    "ISSNLinking": "0066-4804"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Gluconates"
    },
    {
      "RegistryNumber": "J41CSQ7QDS",
      "NameOfSubstance": "Zinc"
    },
    {
      "RegistryNumber": "R4R8J0Q44B",
      "NameOfSubstance": "gluconic acid"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Administration, Oral"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adolescent"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Child"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Clinical Trials as Topic"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Common Cold"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "Gluconates"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "Zinc"
    }
  ]
}